Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Inactivated H1N1 Vaccine Clear all

Conditions: Hematopoietic Stem Cell Transplant, Hematologic Malignancy
Interventions: Influenza vaccine; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Influenza
Interventions: Inactivated H1N1 vaccine; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: Flublok, Afluria; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 2,640 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 14
States / cities: Tucson, Arizona • Coral Gables, Florida • Savannah, Georgia + 11 more

Conditions: Atopic Dermatitis
Interventions: Fluzone® Intradermal (Sanofi Pasteur Inc.); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine, Inactivated H1N1 Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 805 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 2 more

Conditions: Human Influenza
Interventions: Recombinant Influenza Vaccine, Inactivated Influenza Vaccine; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 254,648 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Oakland, California

Conditions: Influenza, Human
Interventions: Investigational aIIV4c, IIV4c, aIIV4, RIV4; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 50 Years and older
Enrollment: 471 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 21
States / cities: Mobile, Alabama • Tempe, Arizona • Jacksonville, Florida + 17 more

Conditions: Avian Influenza, Influenza Immunisation
Interventions: A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, Phosphate Buffered Saline (PBS) diluent; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 50 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza, Influenza Immunisation
Interventions: Influenza Virus Quadrivalent Inactivated Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 9 Years to 99 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Influenza, Influenza Immunisation
Interventions: Influenza Virus Quadrivalent Inactivated Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 15 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: Fluzone® (Aventis Pasteur inactivated influenza vaccine); Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 1,316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Influenza
Interventions: Placebo, Trivalent Inactivated Influenza; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: St Louis, Missouri • Durham, North Carolina • Nashville, Tennessee + 2 more

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine, Trivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 531 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Atlanta, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more

Conditions: HIV
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 6 Months to 25 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Influenza
Interventions: DNA vaccine, TIV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more

Conditions: Influenza
Interventions: Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 2 Years to 9 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Rochester, New York

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza, Human
Interventions: BPL-1357 IM, BPL-1357 IN, Placebo IM, Placebo IN; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Bethesda, Maryland • Galveston, Texas

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Iowa City, Iowa • Cincinnati, Ohio • Seattle, Washington

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: Baltimore, Maryland • St Louis, Missouri • Durham, North Carolina + 3 more

Conditions: Influenza
Interventions: MF59-eH1N1_f; Biological
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 2,719 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 583 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Baltimore, Maryland • Kansas City, Missouri • St Louis, Missouri + 6 more

Search by objective public record fields.

Influenza Vaccine Post Allogeneic Transplant

Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus

Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot

Sanofi H1N1 + TIV - Adults and Elderly

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

2013/2017 H7N9 Prime-Boost Interval

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies

Age and Response to Flu Vaccines

Development of Childhood Anti-Influenza Immunity

Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine

Th1 Response to Influenza: Aging and Vaccine Efficacy

H1N1 Vaccine in Pregnant Women

Sanofi Pasteur, TIV + H1N1, Pediatric Population

Immunogenicity of Inactivated Swine H1N1 Vaccine In HIV Infected Children - The Miami Cohort Study

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Influenza Vaccine in Lung Transplant Patients - Seroprotection

BPL-1357 Against H1N1 Influenza Virus Challenge

CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

Novartis H1N1 Vaccine in Pregnant Women

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels